Prescription Pricing for the People Act of 2025

Bill 119 s 527, also known as the "Pharmaceutical Supply Chain Intermediaries Study Act," is a proposed piece of legislation that aims to address the role of intermediaries in the pharmaceutical supply chain. The bill specifically calls for the Federal Trade Commission (FTC) to conduct a comprehensive study on the impact and influence of intermediaries within the pharmaceutical industry.

The main objective of the study is to provide Congress with valuable insights and policy recommendations regarding the role of intermediaries in the pharmaceutical supply chain. This includes examining how intermediaries such as pharmacy benefit managers (PBMs) and wholesalers impact drug pricing, access to medications, and overall market competition.

The bill emphasizes the importance of transparency and accountability within the pharmaceutical supply chain, highlighting the need for a better understanding of how intermediaries operate and their potential effects on consumers, healthcare providers, and pharmaceutical manufacturers. Overall, Bill 119 s 527 seeks to inform Congress on potential policy changes that could improve the efficiency and fairness of the pharmaceutical supply chain, ultimately benefiting patients and promoting a more competitive and transparent marketplace for prescription medications.